Document is current

Article History

Received: 3 April 2025

Accepted: 23 June 2025

First Online: 10 July 2025

Declarations

:

: Shoko Takano received research funding from PDRadiopharma Inc. Anri Inaki received research funding from Peptidream Inc., Telix Pharmaceuticals Japan K.K., and Hitachi, Ltd. Kenji Hirata received research funding from GE HealthCare Japan Corporation, Sumitomo Heavy Industries, Ltd., and Nihon Medi-Physics Co., Ltd. Richard B. Sparks received consulting funding from Novartis through Imaging Endpoints for the dosimetry analysis. Masahiko Sato, Satoshi Nomura, Toru Hattori, and Hiroya Kambara are employees of Novartis Pharma K.K. Quyen Nguyen is an employee of Novartis Pharma AG. Tohru Shiga received research funding from Sumitomo Heavy Industries, Ltd. and AMS Planning. Makoto Hosono received honoraria from Novartis Pharma K.K. Seigo Kinuya has no conflict of interest to declare. No other potential conflict of interest relevant to this article was reported.

: All human studies have been approved by the ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and all subsequent revisions. This article does not contain any studies with animals performed by any of the authors. Evaluation of data was approved by the Independent Ethics Committee or Institutional Review Board for each center in accordance with the Declaration of Helsinki.

: All participants provided their informed consent prior to their inclusion in the study.